New injection shows promise for Tough-to-Treat skin cancer
NCT ID NCT04570332
Summary
This study tested whether injecting a new drug called BO-112 directly into tumors, along with the standard immunotherapy pembrolizumab, could help patients with advanced melanoma whose cancer had stopped responding to previous immunotherapy. The trial involved 42 adults with stage III or IV melanoma who had progressed after anti-PD-1 treatment. Researchers measured if tumors shrank, how long responses lasted, and monitored side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
-
Centre Hospitalier Universitaire de Grenoble
Grenoble, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, France
-
Centre Hospitalier Universitaire de Nice
Nice, France
-
Clínica Universidad de Navarra
Pamplona, Spain
-
H. General Universitario de Valencia
Valencia, Spain
-
H. Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
-
H. Universitari Quirón Dexeus
Barcelona, Spain
-
Hopital Lyon Sud
Lyon, France
-
Hospital Clara Campal - HM Sanchinarro
Madrid, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
-
Hôpital Ambroise-Paré
Paris, France
-
Institut Gustave Roussy
Paris, France
-
MD Anderson Cancer Center
Madrid, Spain
Conditions
Explore the condition pages connected to this study.